MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21873/anticanres.18338

Медицинская библиотека · Anticancer research · 2026

Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells.

Kim Jinsoo, Han Qinghong, Li Shukuan, Miyashi Yuta, Ishiguro Tomoyuki, Bouvet Michael, Hoffman Robert M

СтатьяПеревод в очереди

Аннотация

BACKGROUND/AIM: Approximately 30% of all cancers have mutations in the KRAS proto-oncogene, GTPase (KRAS), and approximately 88% of pancreatic cancer tumors have mutations in KRAS. Recently, a novel KRAS inhibitor, daraxonrasib, with activity against both wild-type and mutant KRAS, has been developed and has shown efficacy in a phase III clinical trial of recurrent pancreatic-cancer patients, but with significant side-effects. In the present report, we determined whether daraxonrasib is synergistic with recombinant methioninase (rMETase) on pancreatic cancer cells that have the KRAS G12D mutation, compared to normal fibroblasts.

MATERIALS AND

METHODS

Cell viability was measured with the WST-8 reagent. The half-maximal inhibitory concentrations (IC50) of rMETase and daraxonrasib were determined on PANC-1 human pancreatic cancer cells and Hs-27 human normal fibroblasts in vitro. The viability of PANC-1 and Hs-27 cells treated with rMETase alone, DXR alone, or a combination of rMETase and daraxonrasib was determined at their respective IC50 values.

RESULTS

The IC50 values of daraxonrasib were 10.5 μM for PANC-1 and 8.4 μM for Hs-27. The IC50 values of rMETase were 0.47 U/ml for PANC-1 and 0.42 U/ml for Hs-27. Daraxonrasib alone and rMETase alone showed significantly higher cytotoxicity towards PANC-1 cancer cells than Hs-27 fibroblasts. The combination of daraxonrasib and rMETase demonstrated selective synergistic cytotoxicity toward PANC-1 cells compared to normal Hs-27 fibroblasts (p<0.05).

CONCLUSION

The present results suggest that the combination of daraxonrasib and rMETase has clinical potential for lowering the effective dose of daraxonrasib, thereby reducing daraxonrasib-associated side-effects, as well as increasing its efficacy.

Для цитирования: Kim Jinsoo, Han Qinghong, Li Shukuan, Miyashi Yuta, Ishiguro Tomoyuki, Bouvet Michael, Hoffman Robert M. Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells.. Anticancer research. 2026. DOI: 10.21873/anticanres.18338.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.